MEDVi vs Hims vs PlexusDx (2026): Pricing, Plans and Genetic-Guided GLP-1 | PlexusDx

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Cross-shopping MEDVi and Hims for cash-pay GLP-1 weight loss usually comes down to one question dressed up in marketing copy: how much do I have to commit on day one? MEDVi advertises $179 for month one and $299/month thereafter on a no-contract, month-to-month plan. Hims advertises $199/month for compounded semaglutide injections, but that headline price is gated behind a 6-month upfront payment of $1,194 before your first vial ships. PlexusDx Weight Management Protocols sit alongside both as a third pricing model: cash-pay, no membership, no upfront commitment, with the optional Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after your first month). This is a three-way comparison — pricing, medication source, oversight, refunds, state availability, and where the genetic baseline changes the math.

MEDVi vs Hims vs PlexusDx — quick decision frame

Three different pricing logics describe these platforms. MEDVi is an all-inclusive compounded-medication platform with a low first-month price and no contract: $179 first month, $299/month after that, cancellable month-to-month with 72 hours' notice. Hims markets a lower per-month price — $199/month for compounded semaglutide injections — but the price requires you to prepay six months ($1,194) on day one. PlexusDx Weight Management Protocols are cash-pay, no-membership, no-upfront compounded GLP-1 plans across four mechanism classes: Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, and GLP-Squared dual-compound at $249/mo. PlexusDx is available in all 50 states (five require a scheduled live consultation rather than async intake). MEDVi is available in 49 states (not North Dakota); Hims weight loss has a narrower state map — eligibility is checked during intake. None of the three accept insurance for compounded medication; all three accept HSA/FSA cards.

The real annual cost: MEDVi vs Hims vs PlexusDx

Cash-pay, no-insurance math is where the three platforms separate. MEDVi's standard semaglutide plan totals roughly $3,468/year ($179 month one + $299 × 11). Hims' $199/month compounded semaglutide plan totals about $2,388/year — but the $1,194 prepayment is non-refundable for unused months in most cases, so the "savings" only materialize if you stay on the program for the full six months. PlexusDx pricing is structured differently: Microdose GLP-1 Protocol at $129/mo flat is $1,548/year, Semaglutide Injection at $149/mo is $2,148–$2,748/year, Tirzepatide Injection at $249/mo is $2,748–$3,708/year, and GLP-Squared at $249/mo is $2,148–$3,900/year. Add the Precision Peptide Genetic Test for $99 as an add-on after month one and the genetic-baseline-included totals stay below MEDVi at the entry tier and competitive with Hims' fully-prepaid annualized rate — without the upfront-commitment risk. If you're not sure GLP-1 therapy will be tolerated long enough to recoup a 6-month prepayment, the upfront-commitment risk is the variable Hims' $199/month price hides.

Compounded vs FDA-approved branded — what each platform actually dispenses

This is the substantive medication difference and it's worth understanding before you sign up. MEDVi dispenses compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies. Hims' core weight-loss path also dispenses compounded semaglutide as injections, with brand-name Wegovy, Ozempic, Zepbound, and Mounjaro available at insurance-dependent pricing for patients who qualify. Hims briefly launched a $49–$99/mo compounded oral semaglutide pill in early February 2026, then withdrew it within days after FDA scrutiny and a Novo Nordisk patent infringement filing — verify current oral availability directly on hims.com. PlexusDx Weight Management Protocols also dispense compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies, but across four mechanism classes — weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and sema+tirz dual-compound stacks. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; only the branded finished drugs (Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Saxenda, Trulicity, Victoza) carry FDA approval. The choice between a compounded and a branded path is about FDA approval status of the finished product, supply consistency, and which regulatory framework governs your medication — not about effectiveness of the active ingredient.

Safety, side effects, and clinical oversight

All three programs prescribe medications in the GLP-1 receptor agonist class (and tirzepatide, a GIP/GLP-1 dual agonist). The labeled side-effect profile for the branded equivalents is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented; the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies. Clinical oversight differs by platform. MEDVi routes through a licensed clinician and a compounding pharmacy with 24/7 messaging access. Hims routes through licensed providers and affiliated pharmacies via its app, with provider check-ins and lab work where required. PlexusDx uses licensed U.S. compounding pharmacies and a clinical team that, when the genetic test is included, reviews your Peptide Pathways Report before titration — a stratification step neither MEDVi nor Hims performs. None of these compounded-medication programs is FDA-approved for the finished product; the FDA has noted that some compounded semaglutide products use salt forms it considers different active ingredients, and has cautioned that compounded products should not be marketed as equivalent to FDA-approved medications.

Refunds, cancellation, and commitment risk

This is where the three platforms differ the most for first-time GLP-1 patients. MEDVi is month-to-month with no contract; cancellation requires 72+ hours' notice before the next billing date, and any cycle already shipped to the pharmacy is non-refundable. MEDVi also offers a money-back guarantee after five consecutive months on-program if you haven't lost weight, refunded minus a 25% consultation fee. Hims' lowest advertised semaglutide price requires a 6-month prepaid commitment of $1,194; cancellation is generally allowed with 48+ hours' notice before processing, but prepaid months are typically non-refundable, and Hims does not offer a comparable weight-loss guarantee. PlexusDx Weight Management Protocols are billed monthly with no membership fee and no prepayment requirement; the optional Precision Peptide Genetic Test is a one-time charge ($298 standalone or $99 add-on after month one), not a recurring fee. The commitment-risk frame matters most if you're new to GLP-1 therapy — an estimated 15–25% of patients discontinue within the first 8–12 weeks because of nausea, gallbladder pain, or response that doesn't justify the cost. A no-prepayment plan keeps that exit cheap.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither MEDVi nor Hims performs this step — both rely on a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors that same conversation to a measurable genetic baseline, available standalone at $298 or as a $99 add-on after your first month on any protocol.

Which one fits — a four-question decision frame

Question 1: Are you confident you'll stay on GLP-1 therapy for at least six months? If yes, PlexusDx $149/mo prepaid plan is the lowest sticker price for compounded semaglutide injections among the three. Question 2: Do you want low first-month risk and the option to walk away after one or two months? PlexusDx's Microdose GLP-1 Protocol at $129/mo flat are the lowest-commitment entry points. Question 3: Do you want compounded tirzepatide at a transparent monthly cash-pay price? PlexusDx Tirzepatide Injection at $249/mo and PlexusDx Tirzepatide Oral at $279/mo are direct cash-pay options; MEDVi compounded tirzepatide starts at $279 first month and runs $249-$369/mo after; Hims does not currently advertise compounded tirzepatide at a transparent cash-pay price. Question 4: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only option of the three that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Can I use insurance with MEDVi, Hims, or PlexusDx?

Neither MEDVi nor Hims accepts insurance directly for compounded medications, and PlexusDx is cash-pay with no insurance billing for any protocol. All three accept HSA and FSA cards. If your insurance covers a brand-name finished GLP-1 (Wegovy, Ozempic, Zepbound, Mounjaro), going through your own physician for that prescription is usually cheaper than any cash-pay compounded plan.

Is MEDVi cheaper than Hims for compounded semaglutide?

It depends on commitment. Hims is cheaper per month at $199/mo — but only if you prepay $1,194 upfront for six months. MEDVi is cheaper if you want month-to-month flexibility and don't want to risk prepaid funds: $179 first month, then $299/mo. PlexusDx Semaglutide Injection at $149/mo is competitive with both on a no-prepayment basis.

What happened to Hims' $49 oral semaglutide pill?

Hims launched a compounded oral semaglutide pill at $49–$99/mo in early February 2026. Within days, the FDA announced enforcement steps against non-FDA-approved GLP-1 products, HHS referred Hims to the DOJ, and Novo Nordisk filed a patent infringement lawsuit. Hims withdrew the pill on February 7, 2026. PlexusDx offers a daily oral compounded semaglutide tablet through Semaglutide Oral at $249/mo across six dose levels.

Does MEDVi or Hims offer compounded tirzepatide?

MEDVi offers compounded tirzepatide starting at $279 first month, with ongoing pricing from $249-$369/mo depending on dose, available as injection or tablet. Hims does not currently advertise compounded tirzepatide at a transparent cash-pay price — it offers brand-name Zepbound and Mounjaro at insurance-dependent rates. PlexusDx Tirzepatide Injection at $249/mo and Tirzepatide Oral at $279/mo are direct cash-pay tirzepatide options across six and seven dose levels respectively.

Are compounded GLP-1 medications safe?

Compounded drugs are legal when prescribed by a licensed clinician and filled by a licensed pharmacy based on individual medical necessity, but compounded semaglutide and tirzepatide are not FDA-approved finished drug products and have not been evaluated by the FDA for the same outcomes as the branded equivalents. The boxed warning for thyroid C-cell tumors based on rodent studies applies to both semaglutide and tirzepatide. All three platforms route through licensed U.S. compounding pharmacies and licensed prescribers; discuss any GLP-1 decision with your own clinician.

Which states are covered?

MEDVi is available in 49 states (not North Dakota). Hims weight loss is not available in all 50 states — eligibility is checked during intake. PlexusDx Weight Management Protocols are available in all 50 states; five states require a scheduled live consultation rather than async intake.

Is the Precision Peptide Genetic Test required to use a PlexusDx protocol?

No. The Precision Peptide Genetic Test is optional. It's $298 standalone or $99 as an add-on after your first month on any protocol. Patients who want a genetic baseline informing dose decisions before titration choose to add it; patients comfortable starting from a population-average titration schedule can skip it.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Cost, Semaglutide Cost, Tirzepatide Costs, Cheapest GLP-1.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for MEDVi and Hims is based on each provider's published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.